Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.87 USD

28.87
12,948,956

-0.22 (-0.76%)

Updated Sep 30, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer

AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.

How Will Pfizer's (PFE) Key Drugs Perform in Q4 Earnings?

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Sundeep Ganoria  headshot

Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH

Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.

Pfizer as the Bull of the Day and Mesa Air Group have been highlighted as Zacks Bull and Bear of the Day

Pfizer as the Bull of the Day and Mesa Air Group have been highlighted as Zacks Bull and Bear of the Day.

Bryan Hayes headshot

Bull of the Day: Pfizer Inc. (PFE)

With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.

Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?

Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.

Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat

Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program

AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.

Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth

Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Is a Surprise Coming for Pfizer (PFE) This Earnings Season?

Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Best Growth Stocks to Buy for February 4th

CROX, PFE, and AAPL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 4, 2022

The Zacks Analyst Blog Highlights: Hasbro Inc., Pfizer Inc., Twilio Inc., CDW Corp. and Annaly Capital Management Inc

Hasbro Inc., Pfizer Inc., Twilio Inc., CDW Corp. and Annaly Capital Management Inc are highlighted in this Analyst Blog Article.

Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales

Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.

Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M

Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.

Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests

Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.

Incyte (INCY) to Report Q4 Earnings: What's in the Offing?

Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.

Best Growth Stocks to Buy for February 3rd

CROX, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 3, 2022

Nalak Das headshot

5 Corporate Bigwigs to Buy Ahead of Earnings Next Week

Five corporate bigwigs will report fourth-quarter 2021 earnings results next week. These are: HAS, PFE, TWLO, CDW and NLY.

Zacks.com featured highlights include: Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc

Pfizer, The Kroger Co., Archer-Daniels-Midland Co., HP Inc. and Jones Lang LaSalle Inc are highlighted in this Screen of the Week article.

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Is a Beat Likely for Pfizer (PFE) This Earnings Season?

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Is a Beat Likely for Amgen (AMGN) This Earnings Season?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing

Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.

Sweta Killa headshot

5 Cheap Dividend Growth Stocks to Bet Amid Volatility

Pfizer (PFE), Kroger (KR), Archer-Daniels (ADM), HP Inc. (HPQ) and Jones Lang (JLL) seems compelling cheap picks amid volatility.